<DOC>
	<DOCNO>NCT01671956</DOCNO>
	<brief_summary>This randomize , double blind , placebo-controlled , parallel group multi-center study adult patient active moderate severe UC . Eligible patient randomly assign 2:1 ratio one two treatment group , bertilimumab 10 mg/kg match placebo , respectively</brief_summary>
	<brief_title>Evaluation Safety , Efficacy , Pharmacokinetic Pharmacodynamic Bertilimumab Patients With Active Moderate Severe Ulcerative Colitis</brief_title>
	<detailed_description>This randomize , double blind , placebo-controlled , parallel group multi-center study adult patient active moderate severe UC . Eligible patient randomly assign 2:1 ratio one two treatment group , bertilimumab 10 mg/kg match placebo , respectively . The study consist three period : screening period two week , 4-week double-blind treatment period ( three IV infusion 2-week interval ) , safety efficacy follow-up period approximately 9 week . Bertilimumab recombinant human IgG4 monoclonal antibody neutralizes human eotaxin-1 ( eotaxin ) . Bertilimumab administer every week 4-weeks , IV infusion 30 minute .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Males female , 18 70 year age inclusive . 2 . Diagnosed active moderate severe UC per standard diagnostic criterion minimum 3 month : Mayo score 612 ( inclusive ) Screening Visit Endoscopic evidence active mucosal disease , assess flexible sigmoidoscopy , Endoscopic Finding Subscore ≥2 ( assess centrally ) Rectal Bleeding Subscore ≥1 Physician 's Global Assessment ( PGA ) Subscore ≥2 . 3 . Levels eotaxin1 biopsied colon tissue ≥100 pg/mg protein . 4 . Adequate cardiac , renal hepatic function determine Investigator demonstrate screen laboratory evaluation physical examination result ; finding must within normal limit judge clinically significant Investigator . 1 . History colonic rectal surgery hemorrhoidal surgery appendectomy . 2 . Currently receive total parenteral nutrition ( TPN ) . 3 . Positive Clostridium difficile toxin stool assay . 4 . Tested positive active/latent mycobacterium tuberculosis ( TB ) infection . 5 . Pregnant breastfeeding , plan become pregnant study . 6 . Males young childless plan child future . 7 . Known hypersensitivity bertilimumab drug excipients . 8 . History infection require administration IV antibiotic , antiviral antifungal medication within 30 day Screening oral antiinfective agent within 14 day Screening . 9 . Severe UC evidence follow sign toxicity : heart rate &gt; 100 beats/min rest , temperature &gt; 37.8°C , hemoglobin &lt; 10.0 g/dL . 10 . Ulcerative proctitis , define disease limit less 15 cm anal verge . 11 . Received vaccine immunostimulator within 4 week prior screen . 12 . Use &gt; 4.8 g mesalazine equivalent within 2 week prior screen visit . Mesalazine ≤4.8 g allow dose 2 week prior screen visit stable . 13 . Use systemic corticosteroid exceed equivalent 20 mg/day prednisone within four week prior screen visit ( see Section 6.9.1 ) . 14 . Change dose immunosuppressive drug ( e.g. , corticosteroid , 6mercaptopurine [ 6MP ] , azathioprine ) within four week prior screen visit . 15 . Use TNFblockers ( e.g. , infliximab adalimumab ) within 60 day screen visit . 16 . Use chronic nonsteroidal antiinflammatory ( NSAID ) therapy . Occasional use NSAIDs acetaminophen headache , arthritis , myalgia , menstrual cramp , etc. , daily use low dose ( 81162 mg ) aspirin cardiovascular prophylaxis allow . 17 . Patients diagnose : Crohn 's disease Diverticulitis diverticulosis Indeterminate colitis ( inability distinguish UC Crohn 's disease [ assess Investigator ] ) Microscopic colitis ( collagenous lymphocytic colitis ) Ischemic infectious colitis Clostridium difficile colitis within 90 day screen visit Parasitic disease within 90 day screen visit Systemic fungal infection within 90 day screen visit . 18 . History positive serology hepatitis B C , human immunodeficiency virus ( HIV ) infection . 19 . Congenital acquire immunodeficiency ( e.g. , common variable immunodeficiency , organ transplantation ) . 20 . Clinically significant abnormal laboratory test result , unless regard Investigator related UC , include limited : Hemoglobin level &lt; 10.0 g/dL White blood cell count &lt; 3 x 103/µL Lymphocyte count &lt; 0.5 x 103/µL Platelet count &lt; 100 x 103/µL &gt; 1200 x 103/µL Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 upper limit normal ( ULN ) Alkaline phosphatase &gt; 3 ULN Serum creatinine &gt; 2 ULN . 21 . Active abuse alcohol drug . 22 . Known malignancy history malignancy could reduce life expectancy . 23 . Any condition , opinion Investigator , would place patient unacceptable risk participate study protocol . 24 . Participation clinical trial investigational ( unapproved ) product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>IBD</keyword>
	<keyword>UC</keyword>
	<keyword>Colitis</keyword>
	<keyword>Ulcerative Colitis</keyword>
</DOC>